Clinical Trial

Omic Technologies to Track Resistance to Palbociclib in Metastatic Breast Cancer

Study acronym: OMERIC
Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 17, 2026 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a monocentric cohort study, prospective and interventional with minimal risks and constraints for advanced breast cancer. The planned interventions are collection of biological samples at different times. The study will aim to do a descriptive analysis of omics profiles evolution (tumor, volatile organic components) over time, before and after disease progression under Palbociclib treatment with a clinical-biological database.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2020-11-27; most recent amendment 2026-03-16.
Status change: Recruiting → Active, Not Recruiting 2024-12-11
Trial Details
NCT Number NCT04653740
Lead Sponsor Centre Oscar Lambret
Collaborators: Laboratoire PRISM - Michel SALZET
Conditions Advanced Breast Cancer
Enrollment 25 participants
Start Date 2020-09-08
Primary Completion 2026-06 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2026-03-17